CD274 and neoplasm: Compared to approved antibodies in the clinic, CA-170 offers the convenience of oral dosing, shorter half-life to better management of adverse events, dual inhibition of PD-L1 and VISTA to potentially achieve anti-tumor response in patients with the activation of both these checkpoint pathways.